152 related articles for article (PubMed ID: 15206776)
1. Strategies leading to MT2 selective melatonin receptor antagonists.
Spadoni G; Bedini A; Piersanti G; Mor M; Rivara S; Tarzia G
Adv Exp Med Biol; 2003; 527():577-85. PubMed ID: 15206776
[TBL] [Abstract][Full Text] [Related]
2. New selective ligands of human cloned melatonin MT1 and MT2 receptors.
Audinot V; Mailliet F; Lahaye-Brasseur C; Bonnaud A; Le Gall A; Amossé C; Dromaint S; Rodriguez M; Nagel N; Galizzi JP; Malpaux B; Guillaumet G; Lesieur D; Lefoulon F; Renard P; Delagrange P; Boutin JA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):553-61. PubMed ID: 12764576
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
Hu Y; Chan KH; He X; Ho MK; Wong YH
PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening assay for new ligands at human melatonin receptors.
Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
[TBL] [Abstract][Full Text] [Related]
5. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies.
Juszczak M; Roszczyk M; Kowalczyk E; Stempniak B
J Physiol Pharmacol; 2014 Dec; 65(6):777-84. PubMed ID: 25554981
[TBL] [Abstract][Full Text] [Related]
6. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
7. Investigational selective melatoninergic ligands for receptor subtype MT2.
Wan N; Zhang FF; Ju J; Liu DZ; Zhou SY; Zhang BL
Mini Rev Med Chem; 2013 Aug; 13(10):1462-74. PubMed ID: 23815579
[TBL] [Abstract][Full Text] [Related]
8. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
[TBL] [Abstract][Full Text] [Related]
9. Docking studies for melatonin receptors.
Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
[TBL] [Abstract][Full Text] [Related]
10. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
[TBL] [Abstract][Full Text] [Related]
11. (R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents.
Sun LQ; Takaki K; Chen J; Bertenshaw S; Iben L; Mahle CD; Ryan E; Wu D; Gao Q; Xu C
Bioorg Med Chem Lett; 2005 Mar; 15(5):1345-9. PubMed ID: 15713384
[TBL] [Abstract][Full Text] [Related]
12. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
Pévet P
Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
[TBL] [Abstract][Full Text] [Related]
13. Melatonin attenuates rat carotid chemoreceptor response to hypercapnic acidosis.
Tjong YW; Chen Y; Liong EC; Ip SF; Tipoe GL; Fung ML
J Pineal Res; 2004 Jan; 36(1):49-57. PubMed ID: 14675130
[TBL] [Abstract][Full Text] [Related]
14. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands.
Attia MI; Witt-Enderby PA; Julius J
Bioorg Med Chem; 2008 Aug; 16(16):7654-61. PubMed ID: 18657980
[TBL] [Abstract][Full Text] [Related]
16. Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity.
Barberino RS; Menezes VG; Ribeiro AEAS; Palheta RC; Jiang X; Smitz JEJ; Matos MHT
Biol Reprod; 2017 Jun; 96(6):1244-1255. PubMed ID: 28595266
[TBL] [Abstract][Full Text] [Related]
17. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).
Ettaoussi M; Pérès B; Errazani A; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
Eur J Med Chem; 2015 Jan; 90():822-33. PubMed ID: 25528336
[TBL] [Abstract][Full Text] [Related]
19. Heterocyclic aminopyrrolidine derivatives as melatoninergic agents.
Sun LQ; Chen J; Mattson RJ; Epperson JR; Deskus JA; Li WS; Takaki K; Hodges DB; Iben L; Mahle CD; Ortiz A; Molstad D; Ryan E; Yeleswaram K; Xu C; Luo G
Bioorg Med Chem Lett; 2003 Dec; 13(24):4381-4. PubMed ID: 14643330
[TBL] [Abstract][Full Text] [Related]
20. The MT2 receptor stimulates axonogenesis and enhances synaptic transmission by activating Akt signaling.
Liu D; Wei N; Man HY; Lu Y; Zhu LQ; Wang JZ
Cell Death Differ; 2015 Apr; 22(4):583-96. PubMed ID: 25501601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
